Biotin (Vitamin B7) (B7)

Biotin, also known as Vitamin B7 or Vitamin H, is a water-soluble B-complex vitamin that acts as an essential cofactor for five carboxylase enzymes involved in critical metabolic processes, including fatty acid synthesis, gluconeogenesis, and amino acid metabolism (PubChem CID 6324). In the context of Lutetium Lu 177 biotin, the biotin moiety is not a biological target but a key component of a pretargeted radioimmunotherapy (PRIT) system. This system utilizes the exceptionally high non-covalent affinity between biotin and streptavidin (Kd ≈ 10^-15 M) to deliver therapeutic radionuclides to tumor cells (PubMed: 16157554). Typically, a streptavidin-conjugated monoclonal antibody is administered first to target tumor-associated antigens such as TAG-72 or CEA. Once the antibody has localized and cleared from the blood, the radiolabeled biotin (Lutetium Lu 177 biotin) is administered, where it rapidly binds to the streptavidin at the tumor site (PubMed: 10450687). This approach allows for high tumor-to-background radiation ratios and reduces dose-limiting toxicities, such as myelosuppression, by ensuring that unbound radiolabeled biotin is quickly excreted through the kidneys (PubMed: 11039590). Therefore, while biotin is the chemical moiety specified, the therapeutic targets of the overall regimen are the specific antigens expressed by the malignancy.

Other names

Vitamin B7Vitamin HCoenzyme RD-Biotin177Lu-DOTA-biotin moiety

The biotin moiety acts as a high-affinity ligand that binds to streptavidin-conjugated antibodies previously localized at tumor sites, facilitating the delivery of Lutetium-177 for localized beta-particle radiotherapy (PubMed: 16157554).